The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
TRAIL and apoptosis induction by TNF-family death receptors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pro-survival Function of Akt/Protein Kinase B in Prostate Cancer Cells
Thakkar, H., Chen, X., Tyan, F., Gim, S., Robinson, H. M., Lee, C., Pandey, S., Nwokorie, C., Onwudiwe, N. C., & Srivastava, R. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103321200 · Cited by 117
RetractedDeath Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
The Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
Du, C., Fang, M., Li, Y., Li, L., & Wang, X. (2000) · Cell · doi:10.1016/s0092-8674(00)00008-8 · Cited by 3,513
Two CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., & Vaux, D. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00009-x · Cited by 2,372
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
Self-citationGreen, D. R. (2000) · Cell · doi:10.1016/s0092-8674(00)00003-9 · Cited by 1,008
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., et al. (2001) · Nature · doi:10.1038/35051606 · Cited by 966
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Jo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997) · Immunity · doi:10.1016/s1074-7613(00)80399-4 · Cited by 821
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 775
Fulda, S., Wick, W., Weller, M., & Debatin, K.-M. (2002) · Nature Medicine · doi:10.1038/nm735 · Cited by 741
Chaudhary, P. M., Eby, M., Jasmin, A., Bookwalter, A., Murray, J., & Hood, L. (1997) · Immunity · doi:10.1016/s1074-7613(00)80400-8 · Cited by 711
Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells
Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H., & Kubin, M. Z. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2833 · Cited by 664
A novel receptor for Apo2L/TRAIL contains a truncated death domain
Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00422-2 · Cited by 653
Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 616
Inhibition of Fas death signals by FLIPs
Tschopp, J., Irmler, M., & Thome, M. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80223-9 · Cited by 520
LeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 507
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., Van Elsas, A., Müller, M., Wolff, K., Eichler, H.-G., & Pehamberger, H. (1998) · Nature Medicine · doi:10.1038/nm0298-232 · Cited by 481
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO
Deng, Y., Lin, Y., & Wu, X. (2002) · Genes & Development · doi:10.1101/gad.949602 · Cited by 458
Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R. F., Ashkenazi, A., & de Vos, A. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80207-5 · Cited by 435
Nature's TRAIL—On a Path to Cancer Immunotherapy
Smyth, M. J., Takeda, K., Hayakawa, Y., Peschon, J. J., van den Brink, M. R. M., & Yagita, H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00502-2 · Cited by 366
Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice
Lamhamedi-Cherradi, S.-E., Zheng, S.-J., Maguschak, K. A., Peschon, J., & Chen, Y. H. (2003) · Nature Immunology · doi:10.1038/ni894 · Cited by 348
Cancer gene therapy: fringe or cutting edge?
McCormick, F. (2001) · Nature Reviews Cancer · doi:10.1038/35101008 · Cited by 346
Kim, Y., Suh, N., Sporn, M., & Reed, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202458200 · Cited by 309
Cell surface Death Receptor signaling in normal and cancer cells
Özören, N., & El-Deiry, W. S. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00131-1 · Cited by 289
Self-citationMonleón, I., Martínez-Lorenzo, M. J., Monteagudo, L., Lasierra, P., Taulés, M., Iturralde, M., Piñeiro, A., Larrad, L., Alava, M. A., Naval, J., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.6736 · Cited by 266
Jones, E. Y., Mongkolsapaya, J., Grimes, J. M., Chen, N., Xu, X., Stuart, D. I., & Screaton, G. R. (1999) · Nature Structural Biology · doi:10.1038/14935 · Cited by 253
Temperature-sensitive Differential Affinity of TRAIL for Its Receptors
Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., Mclaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910438199 · Cited by 245
Defining Characteristics of Types I and II Apoptotic Cells in Response to TRAIL
Özören, N., & El-Deiry, W. S. (2002) · Neoplasia · doi:10.1038/sj.neo.7900270 · Cited by 237
Self-citationFulda, S., Meyer, E., Friesen, C., Susin, S. A., Kroemer, G., & Debatin, K.-M. (2001) · Oncogene · doi:10.1038/sj.onc.1204141 · Cited by 223
How melanoma cells evade trail-induced apoptosis
Hersey, P., & Zhang, X. D. (2001) · Nature Reviews Cancer · doi:10.1038/35101078 · Cited by 212
Death receptors and melanoma resistance to apoptosis
Ivanov, V. N., Bhoumik, A., & Ronai, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206456 · Cited by 211
Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells
Mariani, S. M., & Krammer, P. H. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199805)28:05<1492::aid-immu1492>3.0.co;2-x · Cited by 192
Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL
Bodmer, J.-L., Meier, P. F., Tschopp, J., & Schneider, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909721199 · Cited by 182
Johnson, T. R., Stone, K., Nikrad, M. P., Yeh, T. C., Zong, W., Thompson, C. B., Nesterov, A., & Kraft, A. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206656 · Cited by 173
Burns, T. F., & El‐Deiry, W. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103516200 · Cited by 171
Self-citationT cells require TRAIL for optimal graft-versus-tumor activity
Schmaltz, C., Alpdogan, O., Kappel, B. J., Muriglan, S. J., Rotolo, J. A., Ongchin, J., Willis, L. M., Greenberg, A. S., Eng, J. M., Crawford, J. M., et al. (2002) · Nature Medicine · doi:10.1038/nm1202-797 · Cited by 163
The potential of TRAIL for cancer chemotherapy
Nagane, M., Huang, H.-J. S., & Cavenee, W. K. (2001) · APOPTOSIS · doi:10.1023/a:1011336726649 · Cited by 161
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling
El‐Deiry, W. S. (2001) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400943 · Cited by 150
Self-citationThe Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis
Takimoto, R., Wang, W., Dicker, D. T., Rastinejad, F., Lyssikatos, J. P., & El‐Deiry, W. S. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.1.41 · Cited by 142
Self-citationWang, W., Takimoto, R., Rastinejad, F., & El-Deiry, W. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.2171-2181.2003 · Cited by 126
Self-citationWebster, R. G. (2001) · Science · doi:10.1126/science.1065206 · Cited by 111
Lin, T.-Y., Huang, X., Gu, J. H., Zhang, L., Roth, J. A., Xiong, M., Curley, S. A., Yu, Y., Hunt, K. K., & Fang, B. (2002) · Oncogene · doi:10.1038/sj.onc.1205926 · Cited by 110
Hunt, A. E., & Evan, G. I. (2001) · Science · doi:10.1126/science.11546862 · Cited by 101
Frese, S., Pirnia, F., Miescher, D., Krajewski, S., Borner, M., Reed, J. C., & Schmid, R. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206842 · Cited by 101
Antitumor Activity and Prolonged Expression from a TRAIL-Expressing Adenoviral Vector
Lee, J., Hampl, M., Albert, P. S., & Fine, H. A. (2002) · Neoplasia · doi:10.1038/sj.neo.7900245 · Cited by 74
Cited by
The Bcl-2 family: roles in cell survival and oncogenesis
Cory, S., Huang, D. C. S., & Adams, J. M. (2003) · Oncogene · doi:10.1038/sj.onc.1207102 · Cited by 1,463
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
The mechanism of action of BCG therapy for bladder cancer--a current perspective
Redelman-Sidi, G., Glickman, M. S., & Bochner, B. H. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.15 · Cited by 729
Apoptosis and cancer: mutations within caspase genes
Ghavami, S., Hashemi, M., Ande, S. R., Yeganeh, B., Xiao, W., Eshraghi, M., Bus, C. J., Kadkhoda, K., Wiechec, E., Halayko, A. J., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066944 · Cited by 713
mTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607
“TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a mediator of anti-tumor drug activity, and a promising target for the treatment of cancer (Wang and El-Deiry, 2003).”
Background
Metadata
- Authors
- Wang, S., & El-Deiry, W. S.
- Venue
- Oncogene
- Published
- 2003-11-24
- Volume
- 22
- Issue
- 53
- Pages
- 8628-8633
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1970856815
- Cited by
- 871
- References
- 58
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.